查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1560942

2024-2032 年按成分、目標、應用、最終用戶和地區分類的抗體藥物偶聯物市場報告

Antibody Drug Conjugates Market Report by Component, Target, Application, End User, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 141 Pages | 商品交期: 2-3個工作天內

價格

2023年，全球抗體藥物偶聯物市場規模達78IMARC Group美元。

抗體藥物偶聯物 (ADC) 是包含腫瘤靶向抗體的高效生物藥物，這些抗體透過化學方式附著在細胞毒性效應分子上。它們透過可生物分解的連接體將細胞毒性抗癌劑連接到單株抗體(mAb)，並允許健康組織和患病組織之間的敏感分叉，從而將細胞毒性抗癌劑傳遞給受影響的細胞。與標準化療生物活性化合物相比，它們有助於提高 mAb 的細胞殺傷潛力、增強藥物耐受性並限制系統暴露。目前，它們透過靜脈注射進入血流，以避免單株抗體被胃酸和蛋白質水解酶分解。

抗體藥物偶聯物市場趨勢：

由於久坐的生活方式以及經常吸煙和飲酒的人數不斷增加，世界各地癌症的盛行率增加。這與對具有成本效益和成功的癌症治療的需求不斷成長相結合，是推動市場成長的關鍵因素之一。除此之外，現有的連接器經常非特異性地釋放有效負載並導致脫靶毒性，這嚴重影響了ADC的開發。因此，領先企業不斷資助他們的研發 (R&D) 項目，以最佳化現有的化學觸發器並開發新型化學觸發劑以產生高度選擇性的連接體。他們還提出了新穎的接頭-抗體配件，以生產穩定且同質的 ADC，以及額外的接頭-有效負載附件，以允許擴展有效負載。此外，他們還致力於改善吸收、分佈、代謝和排泄，這創造了良好的市場前景。其他主要因素，包括顯著改善醫療基礎設施、提高對癌症治療方法的認知以及引入可裂解連接器技術，預計將推動市場成長。

本報告回答的關鍵問題：

  • 迄今為止，全球抗體藥物偶聯物市場表現如何，未來幾年將如何表現？
  • COVID-19 對全球抗體藥物偶聯物市場有何影響？
  • 主要區域市場有哪些？
  • 基於組件的市場區隔是什麼？
  • 基於目標的市場區隔是什麼？
  • 基於應用程式的市場區隔是什麼？
  • 基於最終用戶的市場區隔是什麼？
  • 產業價值鏈的各個階段是什麼？
  • 該行業的關鍵促進因素和挑戰是什麼？
  • 全球抗體藥物偶聯物市場的結構如何？
  • 產業競爭程度如何？

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 數據來源
    • 主要來源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球抗體藥物偶聯物市場

  • 市場概況
  • 市場表現
  • COVID-19 的影響
  • 市場預測

第 6 章：市場區隔：按組成部分

  • 單株抗體
    • 市場趨勢
    • 市場預測
  • 連結器
    • 市場趨勢
    • 市場預測
  • 細胞毒劑
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第 7 章：市場區隔：按目標

  • 抗體-蛋白質毒素綴合物
    • 市場趨勢
    • 市場預測
  • 抗體螯合放射性核種綴合物
    • 市場趨勢
    • 市場預測
  • 抗體-小分子藥物偶聯物
    • 市場趨勢
    • 市場預測
  • 抗體-酵素結合物
    • 市場趨勢
    • 市場預測

第 8 章：市場區隔：按應用

  • 淋巴瘤
    • 市場趨勢
    • 市場預測
  • 卵巢癌
    • 市場趨勢
    • 市場預測
  • 肺癌
    • 市場趨勢
    • 市場預測
  • 乳癌
    • 市場趨勢
    • 市場預測
  • 腦腫瘤
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第 9 章：市場區隔：按最終用戶

  • 醫院
    • 市場趨勢
    • 市場預測
  • 專門癌症中心
    • 市場趨勢
    • 市場預測
  • 學術研究機構
    • 市場趨勢
    • 市場預測
  • 生技公司
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第 10 章：市場區隔：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場趨勢
    • 市場細分：按國家/地區
    • 市場預測

第 11 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 12 章：價值鏈分析

第 13 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 14 章：價格分析

第15章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • ADC Therapeutics SA
    • Astellas Pharma Inc.
    • AstraZeneca plc
    • Celldex Therapeutics Inc.
    • F. Hoffmann-La Roche AG
    • Gilead Sciences Inc.
    • GlaxoSmithKline Plc
    • ImmunoGen Inc
    • Pfizer Inc.
    • Sanofi SA
    • Seagen Inc.
    • Sorrento Therapeutics Inc.
    • Takeda Pharmaceutical Company Ltd.
Product Code: SR112024A4604

The global antibody drug conjugates market size reached US$ 7.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 43.7 Billion by 2032, exhibiting a growth rate (CAGR) of 20.5% during 2024-2032.

Antibody drug conjugates (ADCs) are highly potent biological drugs comprising tumor-targeting antibodies, which are chemically attached to a cytotoxic effector molecule. They deliver cytotoxic anticancer agents to affected cells by connecting them to monoclonal antibodies (mAb) through biodegradable linkers and allowing sensitive bifurcation between healthy and diseased tissues. They assist in increasing the cell-killing potential of mAb, enhancing drug tolerability, and limiting systematic exposure compared to standard chemotherapy bioactive compounds. At present, they are administered intravenously into the bloodstream to avoid gastric acid and proteolytic enzyme degradation of the mAb.

Antibody Drug Conjugates Market Trends:

Due to sedentary lifestyles and the rising number of individuals who smoke and drink regularly, there is an increase in the prevalence of cancer around the world. This, in confluence with the escalating demand for cost-effective and successful cancer treatments, represents one of the key factors bolstering the growth of the market. Apart from this, the existing linkers often release payloads nonspecifically and lead to off-target toxicity, which severely affects the development of ADCs. As a result, leading players are continuously funding their research and development (R&D) projects to optimize the existing chemical triggers and develop novel chemical triggers to generate highly selective linkers. They are also coming up with novel linker-antibody attachments to produce stable and homogenous ADCs and additional linker-payload attachments to allow the expansion of payloads. Moreover, they are focusing on improving the absorption, distribution, metabolism, and excretion, which is creating a favorable market outlook. Other major factors, including considerably improving healthcare infrastructure, increasing awareness about therapies available for cancer treatments, and the introduction of cleavable linker technology, are anticipated to propel the market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global antibody drug conjugates market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on component, target, application and end user.

Breakup by Component:

  • Monoclonal Antibodies
  • Linker
  • Cytotoxic Agent
  • Others

Breakup by Target:

  • Antibody-Protein Toxin Conjugates
  • Antibody-Chelated Radionuclide Conjugates
  • Antibody-Small-Molecule Drug Conjugates
  • Antibody-Enzyme Conjugates

Breakup by Application:

  • Lymphoma
  • Ovarian Cancer
  • Lung Cancer
  • Breast Cancer
  • Brain Tumor
  • Others

Breakup by End User:

  • Hospitals
  • Specialized Cancer Centers
  • Academic Research Institutes
  • Biotechnology Companies
  • Others

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being ADC Therapeutics SA, Astellas Pharma Inc., AstraZeneca plc, Celldex Therapeutics Inc., F. Hoffmann-La Roche AG, Gilead Sciences Inc., GlaxoSmithKline Plc, ImmunoGen Inc, Pfizer Inc., Sanofi S.A., Seagen Inc., Sorrento Therapeutics Inc. and Takeda Pharmaceutical Company Ltd.

Key Questions Answered in This Report:

  • How has the global antibody drug conjugates market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global antibody drug conjugates market?
  • What are the key regional markets?
  • What is the breakup of the market based on the component?
  • What is the breakup of the market based on the target?
  • What is the breakup of the market based on the application?
  • What is the breakup of the market based on the end user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global antibody drug conjugates market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Antibody Drug Conjugates Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Component

  • 6.1 Monoclonal Antibodies
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Linker
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Cytotoxic Agent
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Target

  • 7.1 Antibody-Protein Toxin Conjugates
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Antibody-Chelated Radionuclide Conjugates
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Antibody-Small-Molecule Drug Conjugates
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Antibody-Enzyme Conjugates
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Lymphoma
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Ovarian Cancer
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Lung Cancer
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Breast Cancer
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Brain Tumor
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Others
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Hospitals
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Specialized Cancer Centers
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Academic Research Institutes
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Biotechnology Companies
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast
  • 9.5 Others
    • 9.5.1 Market Trends
    • 9.5.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 ADC Therapeutics SA
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
    • 15.3.2 Astellas Pharma Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 AstraZeneca plc
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Celldex Therapeutics Inc.
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 F. Hoffmann-La Roche AG
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
    • 15.3.6 Gilead Sciences Inc.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 GlaxoSmithKline Plc
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 ImmunoGen Inc
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Pfizer Inc.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Sanofi S.A.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Seagen Inc.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
    • 15.3.12 Sorrento Therapeutics Inc.
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials
    • 15.3.13 Takeda Pharmaceutical Company Ltd.
      • 15.3.13.1 Company Overview
      • 15.3.13.2 Product Portfolio
      • 15.3.13.3 Financials
      • 15.3.13.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Antibody Drug Conjugates Market: Major Drivers and Challenges
  • Figure 2: Global: Antibody Drug Conjugates Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Antibody Drug Conjugates Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Antibody Drug Conjugates Market: Breakup by Component (in %), 2023
  • Figure 5: Global: Antibody Drug Conjugates Market: Breakup by Target (in %), 2023
  • Figure 6: Global: Antibody Drug Conjugates Market: Breakup by Application (in %), 2023
  • Figure 7: Global: Antibody Drug Conjugates Market: Breakup by End User (in %), 2023
  • Figure 8: Global: Antibody Drug Conjugates Market: Breakup by Region (in %), 2023
  • Figure 9: Global: Antibody Drug Conjugates (Monoclonal Antibodies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Antibody Drug Conjugates (Monoclonal Antibodies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Antibody Drug Conjugates (Linker) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Antibody Drug Conjugates (Linker) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Antibody Drug Conjugates (Cytotoxic Agent) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Antibody Drug Conjugates (Cytotoxic Agent) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Antibody Drug Conjugates (Other Components) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Antibody Drug Conjugates (Other Components) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Antibody Drug Conjugates (Antibody-Protein Toxin Conjugates) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Antibody Drug Conjugates (Antibody-Protein Toxin Conjugates) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Antibody Drug Conjugates (Antibody-Chelated Radionuclide Conjugates) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Antibody Drug Conjugates (Antibody-Chelated Radionuclide Conjugates) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Antibody Drug Conjugates (Antibody-Small-Molecule Drug Conjugates) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Antibody Drug Conjugates (Antibody-Small-Molecule Drug Conjugates) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Antibody Drug Conjugates (Antibody-Enzyme Conjugates) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Antibody Drug Conjugates (Antibody-Enzyme Conjugates) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Antibody Drug Conjugates (Lymphoma) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Antibody Drug Conjugates (Lymphoma) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Antibody Drug Conjugates (Ovarian Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Antibody Drug Conjugates (Ovarian Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Global: Antibody Drug Conjugates (Lung Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: Antibody Drug Conjugates (Lung Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Global: Antibody Drug Conjugates (Breast Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Global: Antibody Drug Conjugates (Breast Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Global: Antibody Drug Conjugates (Brain Tumor) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Global: Antibody Drug Conjugates (Brain Tumor) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Global: Antibody Drug Conjugates (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Global: Antibody Drug Conjugates (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: Global: Antibody Drug Conjugates (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: Global: Antibody Drug Conjugates (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: Global: Antibody Drug Conjugates (Specialized Cancer Centers) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: Global: Antibody Drug Conjugates (Specialized Cancer Centers) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: Global: Antibody Drug Conjugates (Academic Research Institutes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: Global: Antibody Drug Conjugates (Academic Research Institutes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: Global: Antibody Drug Conjugates (Biotechnology Companies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: Global: Antibody Drug Conjugates (Biotechnology Companies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: Global: Antibody Drug Conjugates (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: Global: Antibody Drug Conjugates (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: North America: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: North America: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: United States: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: United States: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: Canada: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: Canada: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: Asia-Pacific: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: Asia-Pacific: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: China: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: China: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: Japan: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: Japan: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: India: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: India: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: South Korea: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: South Korea: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Australia: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Australia: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Indonesia: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Indonesia: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Others: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Others: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Europe: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Europe: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Germany: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Germany: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: France: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: France: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: United Kingdom: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: United Kingdom: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Italy: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 78: Italy: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Spain: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 80: Spain: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 81: Russia: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 82: Russia: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 83: Others: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 84: Others: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 85: Latin America: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 86: Latin America: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 87: Brazil: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 88: Brazil: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 89: Mexico: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 90: Mexico: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 91: Others: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 92: Others: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 93: Middle East and Africa: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 94: Middle East and Africa: Antibody Drug Conjugates Market: Breakup by Country (in %), 2023
  • Figure 95: Middle East and Africa: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 96: Global: Antibody Drug Conjugates Industry: SWOT Analysis
  • Figure 97: Global: Antibody Drug Conjugates Industry: Value Chain Analysis
  • Figure 98: Global: Antibody Drug Conjugates Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Antibody Drug Conjugates Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Antibody Drug Conjugates Market Forecast: Breakup by Component (in Million US$), 2024-2032
  • Table 3: Global: Antibody Drug Conjugates Market Forecast: Breakup by Target (in Million US$), 2024-2032
  • Table 4: Global: Antibody Drug Conjugates Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 5: Global: Antibody Drug Conjugates Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 6: Global: Antibody Drug Conjugates Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 7: Global: Antibody Drug Conjugates Market: Competitive Structure
  • Table 8: Global: Antibody Drug Conjugates Market: Key Players